BusinessEmergent Biosolutions Announces Preliminary 2015 Financial Results, Provides 2016 Financial Outlook, and Outlines New Five-Year (2016-2020) Strategic Growth PlanBy Nasdaq OMXJan 11, 2016, 12:01 PM UTC
BusinessCyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016By Nasdaq OMXJan 11, 2016, 12:00 PM UTC
BusinessCoherus and Baxalta Announce CHS-0214 (Investigational Etanercept Biosimilar) Met Primary Efficacy Endpoint in Phase 3 Rheumatoid Arthritis Clinical Study (RaPsODY)By Nasdaq OMXJan 11, 2016, 11:45 AM UTC
BusinessArbutus Provides a Corporate Update and Outlines 2016 MilestonesBy Nasdaq OMXJan 10, 2016, 9:00 PM UTC
BusinessCytokinetics Presents Analyses Demonstrating Predictive Value of Slow Vital Capacity for Clinical Outcomes in ALSBy Nasdaq OMXJan 10, 2016, 5:00 PM UTC
BusinessImmune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305By Nasdaq OMXJan 8, 2016, 8:42 PM UTC
BusinessCalifornia Life Sciences Association (CLSA) Applauds Gov. Brown on Budget that Invests $10 Million in Precision Medicine ResearchBy Nasdaq OMXJan 8, 2016, 6:43 PM UTC
BusinessU.S. IND Becomes Active for BGB-A317, an Anti-PD-1 Monoclonal AntibodyBy Nasdaq OMXJan 8, 2016, 6:07 PM UTC
